CM Hospitalar (VVEO3) Q3 2024 earnings summary

Executive summary

• Net revenue in 3Q24 reached R$2.95 billion, up 3.8% year-over-year, with 9M24 revenue at R$8.67 billion, a 5.9% increase from 9M23.

• Projects initiated earlier in the year yielded strong results in Q3 2024, with operational stability achieved across gross margin and EBITDA margin for the first three quarters.

• Integration and simplification efforts since mid-2023 included incorporating 18 companies, reducing ERPs, and upgrading distribution centers, leading to improved operational quality and cash generation.

• Strategic projects to refocus operations and working capital showed consistent results in 3Q24, including improved cash cycle and lower net debt.

• Focus shifted from rapid expansion to operational excellence, with key projects in supply chain, cost reduction, order-to-cash cycle, and backoffice consolidation showing tangible improvements.

Financial highlights

• Gross profit was R$391.9 million in 3Q24 (down 8.2% vs 3Q23), with a margin of 13.3%.

• Adjusted EBITDA was R$146.8 million in 3Q24 (5.0% margin), down 41.5% year-over-year, but stable sequentially.

• Free cash flow reached R$506.9 million in 3Q24, a significant improvement from R$105.9 million in 3Q23.

• Adjusted net loss was R$56 million in 3Q24, after accounting for non-recurring effects.

• Net debt at 3Q24 was R$2.11 billion, with leverage (ex-M&A) at 3.14x.

Outlook and guidance

• Expectation of further benefits from supply chain and cost reduction projects in coming quarters.

• SG&A savings targeted at R$10 million per month, with full impact expected by mid-2025.

• All distribution centers to have WMS implemented by 2025.

• Anticipation of margin recovery as high-margin service operations normalize and new retail initiatives launch in 2025.

• Corporate restructuring and cost optimization measures are expected to reduce expenses from 4Q24 onward.